ZD6126

ZD6126 is a vascular-targeting agent and a prodrug of N-acetylcolchinol, related to colchicine.^[1] It has shown promising results on tumors in mice.^[2]

Other namesANG 453; AZD 6126; N-Acetylcolchicinol dihydrogenphosphate

CAS Number

• 219923-05-4 ^Y

PubChem CID

• 9896434

ChemSpider

• 8072099 ^N

Quick facts Clinical data, Other names ...

ZD6126

Clinical data
Other names	ANG 453; AZD 6126; N-Acetylcolchicinol dihydrogenphosphate
Identifiers
IUPAC name Phosphoric acid mono-(5-acetylamino-9,10,11-trimethoxy-6,7-dihydro-5H-dibenzo[a,c]cyclohepten-3-yl) ester
CAS Number	219923-05-4 Y
PubChem CID	9896434
ChemSpider	8072099 N
UNII	GBO3S6M9W7
CompTox Dashboard (EPA)	DTXSID20944593
Chemical and physical data
Formula	C20H24NO8P
Molar mass	437.385 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC(=O)N[C@H]1CCC2=CC(=C(C(=C2C3=C1C=C(C=C3)OP(=O)(O)O)OC)OC)OC
InChI InChI=1S/C20H24NO8P/c1-11(22)21-16-8-5-12-9-17(26-2)19(27-3)20(28-4)18(12)14-7-6-13(10-15(14)16)29-30(23,24)25/h6-7,9-10,16H,5,8H2,1-4H3,(H,21,22)(H2,23,24,25)/t16-/m0/s1 N Key:UGBMEXLBFDAOGL-INIZCTEOSA-N N
NY (what is this?)  (verify)

Close

A phase I clinical trial identified gastrointestinal and cardiac effects as limiting dosing.^[3] Two phase II clinical trials were suspended investigating ZD6126 in metastatic renal cell carcinoma and metastatic colorectal cancer.^[4]

ZD6126 was being investigated by AstraZeneca as a vascular disrupting agent (VDA). However, the trials were halted, after it became apparent that ZD6126 was too cardiotoxic at the required doses.^[5]